调节性T细胞和肝细胞癌

Regulatory T cells and hepatocellular carcinoma

调节性T细胞是一类CD4^＋CD25^highFoxp3^＋T细胞，它不仅参与自身免疫性疾病、感染性疾病和移植耐受，而且抑制机体抗肿瘤免疫应答。研究表明，肝细胞癌患者血循环和肿瘤组织中Treg数量增加，参与肝细胞癌的发生发展过程，影响患者生存率与预后。消除Treg免疫抑制有望成为HCC免疫治疗的新方法，同时结合手术切除肿瘤提高机体肿瘤特异性T细胞记忆反应以清除潜在转移灶和预防复发，提高HCC临床疗效。本文就调节性T细胞在HCC发生发展中的作用、与预后的关系及其临床应用前景作一综述。

Regulatory T cells （Tregs） are a subpopulation of CD4^＋T cells highly expressing CD25 and Foxp3. Treg not only involves in autoimmune disease, infection and transplantation tolerance, but also plays a pivotal role in the suppression of anti-tumor immunity during tumor development. Current researches sug- gest the frequency of Treg is increased in tumor tissues and peripheral blood of patients with HCC, which is associated with HCC development, and affect survival rate and prognosis of HCC patients. Depletion of Treg together with surgical resection of the tumor could be a new approach for HCC, which can enhance tumorspecific T cell memory to remove latent metastasis and protect against recurrence for improvement of HCC therapeutic effect. This review presents the role of Treg in HCC development, the relationship between Treg and prognosis and its clinical practice.